Health
Moderna and Merck advance personalized mRNA cancer vaccine after pivotal melanoma trial
The successful late-stage trial results for intismeran autogene mark a breakthrough for personalized mRNA cancer therapies, shifting focus toward regulatory approval and broader oncology applications.
AI · grounded4 of 5 claims single-sourced